Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis

Abstract

[EN] Myelofibrosis (MF) is a chronic myeloproliferative neoplasm (MPN) characterized by clonal proliferation of hematopoietic progenitors, bone marrow fibrosis, and extramedullary hematopoiesis. Thrombotic complications increase morbidity and mortality in MF. The present study had two objectives: to determine the impact of non-MPN driver mutations on the risk of thrombosis in 581 MF patients diagnosed at centers affiliated to the “Grupo Español de enfermedades Mieloproliferativas Filadelfia Negativas” (GEMFIN), and to evaluate the predictive value of the ARTS and VETS models in our series. Our data do not support the usefulness of studying non-MPN driver mutations to evaluate thrombotic risk in MF, but further studies are needed before completely ruling out their impact on arterial risk in this condition.